Skip to main content

BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)

BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

  • RegistryNCT05976555
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMultiple Myeloma
  • SponsorMedical College of Wisconsin
How Phase I Trial of BCMA-TGF-BETA CAR-T Cell… worksNCT059765551 min

What the film says

Read the transcript

Multiple myeloma keeps coming back. CAR T cells against a marker called BCMA can clear it for a time, but most patients eventually relapse.

The idea: armor the cells against the signal the tumor uses to switch them off.

Myeloma bone marrow is rich in TGF-beta, a molecule that quiets immune cells. Here, a patient's T cells receive the BCMA receptor plus a change that makes them insensitive to TGF-beta, so they keep working where ordinary CAR T cells are dampened. The cells are grown with interleukin-7 and -15, favoring younger, longer-lived cells.

An early dose-finding trial in adults after three or more prior therapies, including prior BCMA drugs.

Binod Dhakal leads it at the Medical College of Wisconsin. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT05976555

    TGF-beta in myeloma marrow suppresses immune cells; BCMA receptor + TGF-beta insensitivity; IL-7/IL-15 manufacturing; ≥3 prior lines incl. PI, IMiD, anti-CD38; BCMA-naïve and BCMA-exposed cohorts (+1 more lines)

The drug

What is being tested.

This is dose level 1, the starting dose.

The maximum tolerated dose is yet to be determined.

BCMA-Transforming growth factor-beta (TGFβ) CAR-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Patients will receive one of three dose levels of BCMA-TGFβ CAR-T cells based on our dose escalation design.

The study

How the trial runs.

This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) / interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and/or refractory myeloma that have failed prior therapies.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients must be aged ≥18 years to 80 years old.
  • Patients must have received three prior lines of therapies, including proteasome inhibitor, immunomodulator and a cluster of differentiation (CD) 38 monoclonal antibody:
  • International Myeloma Working Group (IMWG) criteria defines refractory disease as disease progression on or within 60 days of receiving therapy.
  • Patients must have measurable disease, including at least one or more of the following criteria:
  • Serum M-protein ≥0.5 g/dl;
  • Urine M-protein ≥200 mg/24 hrs;

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.